TSX higher on employment data
bioAffinity Technologies, Inc. (NASDAQ:BIAF), currently trading at $0.24 with a market capitalization of $6.8 million, reported Tuesday that it has amended the terms of certain outstanding warrants, according to a statement based on a recent SEC filing.
The company and holders of warrants issued on May 7, 2025, and August 13, 2025, agreed, effective as of August 12, 2025, to increase the floor price of the warrants from $0.10 to $0.15 per share. As a result of this amendment, the total number of shares issuable upon exercise of the May 2025 warrants was reduced from 53,377,497 to 35,584,997.
The company also stated that the August 2025 warrants remain subject to shareholder approval.
The amendments to the May 2025 and August 2025 warrants are described in detail in the company’s exhibits attached to the filing.
bioAffinity Technologies is listed on The Nasdaq Stock Market LLC, with its common stock trading under the symbol NASDAQ:BIAF and its warrants under NASDAQ:BIAFW.
This information is based on a press release statement contained in a recent SEC filing.
In other recent news, bioAffinity Technologies has raised approximately $1.2 million through a private placement and warrant inducement transaction. This financing involved securities purchase agreements with institutional and accredited investors, resulting in the issuance of 990 shares of Series B Convertible Preferred Stock and warrants for about 6.7 million common shares. Additionally, the company has strengthened its intellectual property portfolio with new patents. The Canadian Patent Office has allowed a patent for a method to detect lung disease using flow cytometry analysis of sputum, enhancing protection for their CyPath® Lung diagnostic platform. In China, bioAffinity Technologies received a patent for a cancer therapy targeting CD320 and LRP2 receptors, which involves small interfering RNAs (siRNAs) for cancer treatment. The company also announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors to support the expansion of its lung cancer detection test sales.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.